Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Altimmune

Nasdaq:ALT
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALT
Nasdaq
$42M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, discovers and develops immunotherapies and vaccines to address the unmet medical needs. The last earnings update was 136 days ago. More info.


Add to Portfolio Compare Print
  • Altimmune has significant price volatility in the past 3 months.
ALT Share Price and Events
7 Day Returns
-3.1%
NasdaqGM:ALT
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-1.7%
NasdaqGM:ALT
0%
US Biotechs
-11.5%
US Market
ALT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Altimmune (ALT) -3.1% 61.9% 58.3% -1.7% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • ALT underperformed the Biotechs industry which returned 0% over the past year.
  • ALT outperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
ALT
Industry
5yr Volatility vs Market

ALT Value

 Is Altimmune undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Altimmune. This is due to cash flow or dividend data being unavailable. The share price is $2.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Altimmune's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Altimmune's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ALT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-3.69
NasdaqGM:ALT Share Price ** NasdaqGM (2020-03-27) in USD $2.85
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Altimmune.

NasdaqGM:ALT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALT Share Price ÷ EPS (both in USD)

= 2.85 ÷ -3.69

-0.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Altimmune is loss making, we can't compare its value to the US Biotechs industry average.
  • Altimmune is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Altimmune's expected growth come at a high price?
Raw Data
NasdaqGM:ALT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-19.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Altimmune, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Altimmune's assets?
Raw Data
NasdaqGM:ALT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $3.29
NasdaqGM:ALT Share Price * NasdaqGM (2020-03-27) in USD $2.85
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:ALT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALT Share Price ÷ Book Value per Share (both in USD)

= 2.85 ÷ 3.29

0.87x

* Primary Listing of Altimmune.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Altimmune is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Altimmune's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Altimmune has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALT Future Performance

 How is Altimmune expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-19.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Altimmune expected to grow at an attractive rate?
  • Unable to compare Altimmune's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Altimmune's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Altimmune's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ALT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ALT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -19.8%
NasdaqGM:ALT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -61.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ALT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ALT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 0 -72 1
2023-12-31 0 -60 1
2022-12-31 0 -55 1
2021-12-31 0 -29 1
2020-12-31 2 -21 1
2020-03-28
2019-12-31 6 -20 1
NasdaqGM:ALT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 8 -13 -42
2019-06-30 10 -11 -34
2019-03-31 11 -8 -40
2018-12-31 10 -9 -42
2018-09-30 11 -9 -29
2018-06-30 13 -12 -58
2018-03-31 13 -20 -52
2017-12-31 11 -20 -51
2017-09-30 9 -17 -43
2017-06-30 5 -15 -16
2017-03-31 3 -8 -14
2016-12-31 3 -6 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Altimmune is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Altimmune's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ALT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Altimmune Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.76 -1.76 -1.76 1.00
2023-12-31 -1.53 -1.53 -1.53 1.00
2022-12-31 -2.14 -2.14 -2.14 1.00
2021-12-31 -1.16 -1.16 -1.16 1.00
2020-12-31 -1.26 -1.26 -1.26 1.00
2020-03-28
2019-12-31 -1.52 -1.52 -1.52 1.00
NasdaqGM:ALT Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -3.69
2019-06-30 -4.16
2019-03-31 -7.98
2018-12-31 -15.16
2018-09-30 -32.77
2018-06-30 -85.83
2018-03-31 -95.19
2017-12-31 -118.91
2017-09-30 -123.46
2017-06-30 -57.92
2017-03-31 -68.59
2016-12-31 -49.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Altimmune will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Altimmune's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Altimmune has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALT Past Performance

  How has Altimmune performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Altimmune's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Altimmune does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Altimmune's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Altimmune's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Altimmune's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Altimmune Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 7.81 -42.16 8.91
2019-06-30 9.80 -33.51 8.68
2019-03-31 10.60 -39.96 9.38
2018-12-31 10.33 -42.48 9.77
2018-09-30 10.55 -28.83 8.94
2018-06-30 12.51 -58.41 10.01
2018-03-31 13.13 -51.72 9.70
2017-12-31 10.74 -51.36 8.46
2017-09-30 9.01 -42.90 8.00
2017-06-30 5.32 -15.93 8.25
2017-03-31 3.03 -14.48 6.60
2016-12-31 3.24 -11.46 6.44
2016-09-30 3.00 -10.00 5.01
2015-12-31 4.65 -6.79 4.88
2014-12-31 5.55 -0.59 1.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Altimmune has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Altimmune has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Altimmune improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Altimmune's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Altimmune has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALT Health

 How is Altimmune's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Altimmune's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Altimmune is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Altimmune's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Altimmune's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 396.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Altimmune Company Filings, last reported 5 months ago.

NasdaqGM:ALT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 49.38 0.11 39.20
2019-06-30 56.23 0.42 41.67
2019-03-31 59.32 0.56 44.30
2018-12-31 48.31 0.57 33.72
2018-09-30 39.68 2.01 7.96
2018-06-30 36.32 1.89 4.17
2018-03-31 46.49 0.67 4.56
2017-12-31 48.68 0.65 8.77
2017-09-30 57.07 0.64 17.12
2017-06-30 75.98 0.62 8.37
2017-03-31 29.10 4.34 2.74
2016-12-31 32.21 0.98 2.88
2016-09-30 36.57 1.10 5.10
2015-12-31 43.46 1.08 4.64
2014-12-31 -1.82 0.86 0.13
  • Altimmune's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Altimmune's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Altimmune has sufficient cash runway for more than 3 years based on current free cash flow.
  • Altimmune has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 20.4% each year.
X
Financial health checks
We assess Altimmune's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Altimmune has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALT Dividends

 What is Altimmune's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Altimmune dividends.
If you bought $2,000 of Altimmune shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Altimmune's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Altimmune's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ALT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ALT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Altimmune has not reported any payouts.
  • Unable to verify if Altimmune's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Altimmune's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Altimmune has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Altimmune's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Altimmune afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Altimmune has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALT Management

 What is the CEO of Altimmune's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vipin Garg
COMPENSATION $2,189,964
AGE 61
TENURE AS CEO 1.3 years
CEO Bio

Dr. Vipin K. Garg, Ph.D. has been President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg served as Advisor of Neos Therapeutics, Inc. since June 27, 2018 until July 31, 2018. Dr. Garg served as the Chief Executive Officer at Neos Therapeutics, Inc. since October 22, 2013 until June 27, 2018 and also served as its President since July 2014 until June 27, 2018. Dr. Garg served as Chief Executive Officer and President at Ocera Therapeutics, Inc., until July 15, 2013. He served as the Chief Executive Officer and President at Tranzyme Pharma, Inc. since February 2000. Dr. Garg has over 25 years of biotechnology industry experience in both technical and management positions. He has a proven track record of building and managing both private and publicly traded companies. He served as Chief Executive Officer and President of Tranzyme, Inc. since February 2000 and served as its Director since October 2000. He served as the Chief Operating Officer of Apex Bioscience Inc. He served as Vice President of Product Development and Manufacturing at DNX Inc. and held management positions at Sepracor Inc. and Bio-Response Inc. (acquired by Baxter). He was a Director of Neos Therapeutics, Inc. since October 22, 2013 until June 27, 2018. Dr. Garg served as a Director at The Council for Entrepreneurial Development. He served as Whole Time Director of Visesh Infotecnics Ltd from August 14, 2012 to January 8, 2014 and served as its Additional Director from February 14, 2011 to September 28, 2011. He served as Director at Ocera Therapeutics, Inc. until July 15, 2013. He served as a Director at Tranzyme Pharma, Inc. since February 2000. Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia and M.S. Degree from Delhi University.

CEO Compensation
  • Insufficient data for Vipin to compare compensation growth.
  • Vipin's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Altimmune management team in years:

1.7
Average Tenure
60.5
Average Age
  • The average tenure for the Altimmune management team is less than 2 years, this suggests a new team.
Management Team

Mitch Sayare

TITLE
Executive Chairman
COMPENSATION
$190K
AGE
71

Vipin Garg

TITLE
President
COMPENSATION
$2M
AGE
61
TENURE
1.3 yrs

Will Brown

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$216K
AGE
37
TENURE
1.8 yrs

Sybil Tasker

TITLE
Consultant
COMPENSATION
$546K
AGE
56
TENURE
0.8 yrs

Bertrand Georges

TITLE
Chief Technology Officer
TENURE
2.8 yrs

M. Roberts

TITLE
Chief Scientific Officer
COMPENSATION
$290K
AGE
60
TENURE
7.3 yrs

José Ochoa

TITLE
Chief Business Officer
TENURE
1.7 yrs

M. Harris

TITLE
Chief Medical Officer
AGE
66
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Altimmune board of directors in years:

2.8
Average Tenure
69
Average Age
  • The average tenure for the Altimmune board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mitch Sayare

TITLE
Executive Chairman
COMPENSATION
$190K
AGE
71
TENURE
2.2 yrs

Vipin Garg

TITLE
President
COMPENSATION
$2M
AGE
61
TENURE
1.3 yrs

Philip Hodges

TITLE
Independent Director
COMPENSATION
$60K
AGE
50
TENURE
2.8 yrs

David Drutz

TITLE
Independent Director
COMPENSATION
$55K
AGE
80
TENURE
2.8 yrs

Wayne Pisano

TITLE
Independent Director
COMPENSATION
$18K
AGE
64
TENURE
1.6 yrs

Rich Whitley

TITLE
Member of Scientific Advisory Board
AGE
73

John Petricciani

TITLE
Member of Scientific Advisory Board
AGE
83

Klaus Schafer

TITLE
Independent Director
COMPENSATION
$48K
AGE
69
TENURE
7.7 yrs

John Gill

TITLE
Director
COMPENSATION
$43K
AGE
67
TENURE
15.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
05. Sep 19 Buy Vipin Garg Individual 05. Sep 19 05. Sep 19 20,000 $2.10 $42,000
X
Management checks
We assess Altimmune's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Altimmune has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALT News

Simply Wall St News

Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?

Today, I will be analyzing Altimmune Inc’s (NASDAQ:ALT) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Why Altimmune Inc's (NASDAQ:ALT) Investor Composition Impacts Your Returns

In this analysis, my focus will be on developing a perspective on Altimmune Inc’s (NASDAQ:ALT) latest ownership structure, a less discussed, but important factor. … Although ALT has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … An investor should be encouraged by the ownership of these institutions who are known to be experts in increasing efficiency, improving capital structure and opting for value-accretive policy decisions.Next Steps: ALT's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Is Altimmune Inc (NASDAQ:ALT) Overpaying Its CEO?

View our latest analysis for Altimmune What has ALT's performance been like? … Therefore I will use earnings as a proxy of Enright's performance in the past year. … Typically I'd use market cap and profit as factors determining performance, however, ALT's negative earnings reduces the usefulness of my formula.

Simply Wall St -

Why Altimmune Inc's (NASDAQ:ALT) Ownership Structure Is Important

See our latest analysis for Altimmune NasdaqGM:ALT Ownership_summary Feb 14th 18 Institutional Ownership ALT's 15.49% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … This is a positive sign for potential investors as these firms play an important role in aligning company policy with shareholder returns.Next Steps: ALT's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Is Altimmune Inc (NASDAQ:ALT) On The Right Side Of Disruption?

The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … NasdaqGM:ALT PE PEG Gauge Jan 17th 18 Biotech companies are typically trading at a PE of 29x, above the broader US stock market PE of 20x. … If your initial investment thesis is around the growth prospects of Altimmune, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average.

Simply Wall St -

Is Altimmune Inc's (ALT) CEO Paid Enough Relative To Peers?

Therefore I will use earnings as a proxy of Enright's performance in the past year. … During times of negative earnings, the company may be incurring a period of reinvestment and growth, or it can be an indication of some headwind. … Typically I would look at market cap and earnings as a proxy for performance, however, ALT's negative earnings reduces the usefulness of my formula.

Simply Wall St -

Who Are The Largest Shareholders In Altimmune Inc (ALT)?

See our latest analysis for ALT NasdaqGM:ALT Ownership Summary Nov 16th 17 Institutional Ownership In ALT's case, institutional ownership stands at 17.01%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

ALT Company Info

Description

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, discovers and develops immunotherapies and vaccines to address the unmet medical needs. The company develops HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus that completed the Phase I clinical trial; NasoVAX, an intranasally administered recombinant influenza vaccine that completed Phase 2a clinical trials; and NasoShield, an anthrax vaccine for protection after a single intranasal administration that is in Phase I clinical trial. Its preclinical stage products include ALT-702, a tumor immunostimulant product candidate for treating cancer; and ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Details
Name: Altimmune, Inc.
ALT
Exchange: NasdaqGM
Founded:
$42,341,964
15,014,881
Website: http://altimmune.com
Address: Altimmune, Inc.
910 Clopper Road,
Suite 201S,
Gaithersburg,
Maryland, 20878,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALT Common Shares Nasdaq Global Market US USD 05. May 2017
DB 3G0 Common Shares Deutsche Boerse AG DE EUR 05. May 2017
Number of employees
Current staff
Staff numbers
27
Altimmune employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:20
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.